FDA again expands usage of Regeneron eye drug Eylea

March 25, 2015 3:22 PM

4 0

FDA again expands usage of Regeneron eye drug Eylea

(Reuters) - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.

The Food and Drug Administration decision marked the fourth approval for Eylea, an injectable medicine sold in partnership with French drugmaker Sanofi. Eylea had sales of $2.78 billion in 2014.

Read more

To category page

Loading...